[Featured Stock] Huons Global Soars to Upper Limit on News of COVID-19 Vaccine Production

[Asia Economy Reporter Ji Yeon-jin] On the 15th, Huons Global, a KOSDAQ-listed company, soared to the price limit (30%) following news of the production of the COVID-19 vaccine developed in Russia, hitting a new 52-week high.

Huons Global recorded 51,800 KRW, up 29.8% from the previous day, immediately hitting the upper price limit right after the market opened.

Earlier, the company announced that it would undertake contract manufacturing (CMO) of the Russian COVID-19 vaccine Sputnik V.

A consortium led by Huons Global signed a technology transfer agreement with the Russian sovereign wealth fund, the Russian Direct Investment Fund (RDIF), for the production of the Sputnik V vaccine.

The consortium plans to begin pilot production in August after receiving the technology transfer for vaccine production. Subsequently, the consortium intends to flexibly respond to the quantities requested by RDIF. Huons Global plans to establish facilities capable of producing over 100 million doses per month by mobilizing the capabilities of each company involved.

Sputnik V, developed in Russia, was the world's first COVID-19 preventive vaccine approved in August last year. It has gained attention after the results of Phase 3 clinical trials showing 91.6% efficacy were published in the world-renowned medical journal The Lancet in February.

This content was produced with the assistance of AI translation services.